Show
Sort by
-
Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms : a Belgian national study
-
Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur)
-
- Journal Article
- A1
- open access
Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma : data from the open-label, phase II KEYNOTE-224 trial
-
Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015
-
Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management : Belgian multidisciplinary expert discussion based on a modified Delphi method
-
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
-
- Journal Article
- A1
- open access
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
-
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
-
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digstive Oncology
-
- Journal Article
- A1
- open access
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
-
- Conference Paper
- C3
- open access
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study
-
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer
-
Locoregional and radioisotopic targeted treatment of neuroendocrine tumours
-
Diagnostic pitfalls in digestive neuroendocrine tumours
-
Carcinoid heart disease: a hidden complication of neuroendocrine tumours
-
The role of surgery and transplantation in neuroendocrine tumours
-
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
-
The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
-
The potential role of targeted therapies in the management of neuroendocrine tumours
-
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study
-
A Phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine
-
Sorafenib in advanced hepatocellular carcinoma
-
Dose-finding study using oxaliplatin in combination with fixed dose gemcitabin and radiotherapy in patients with locally advanced pancreatic or biliary tract cancer.
-
- Journal Article
- A1
- open access
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study
-
The HepCar registry : report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium: what is daily practice in HCC?
-
BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma